JUNS news

Latest 1 stories · newest May 20, 2026

JUNS

Jupiter Neurosciences secures $100M term sheet for ALA-002 MDMA rights

Jupiter Neurosciences entered into a term sheet to acquire exclusive U.S. rights to PharmAla's ALA-002, a next-generation MDMA therapeutic, with an upfront payment of $3.33 million and milestone payments. The transaction positions the company to capitalize on President Trump's executive order accele…

M&A May 20, 2026 sentiment +0.80 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same JUNS feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/JUNS/newsSTART FREE